ANEBULO PHARMACEUTICALS INC (ANEB)

US0345691036 - Common Stock

1.9  +0.07 (+3.83%)

After market: 1.93 +0.03 (+1.58%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (10/15/2024, 8:14:09 PM)

After market: 1.93 +0.03 (+1.58%)

1.9

+0.07 (+3.83%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-31.65%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap49.27M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ANEB Daily chart

Company Profile

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.

Company Info

ANEBULO PHARMACEUTICALS INC

Jfl Capital Management, 1017 Rr 620 S, Suite 107

Lakeway TEXAS

P: 17372035270

CEO: Daniel Schneeberger

Employees: 3

Website: https://www.anebulo.com/

ANEB News

News Image20 days ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
News Image22 days ago - Market News VideoMonday Sector Laggards: Drugs, Biotechnology Stocks
News Image3 months ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
News Image4 months ago - Lifecore Biomedical, Inc.Lifecore Biomedical Announces Cooperation Agreement with 22NW

Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board

News Image5 months ago - InvestorPlaceANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.

News Image5 months ago - BusinessInsiderANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anebulo Pharmaceuticals (NASDAQ:ANEB) just reported results for the third quart...

ANEB Twits

Here you can normally see the latest stock twits on ANEB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example